Carlo Cattrini 🇮🇹

Medical Advisor GI Oncology at @AstraZeneca. Prior Oncologist at AOU #Novara, @UniAvogadro. PhD @UniGenova. Prior #ESMO Fellow at @CNIO_Cancer Madrid

[David Olmos @Dolmos77]

1/9 Glad to announce that the #CAPTURE study manuscript has been published today in @Annals_Oncology
Would you like to learn more about it? Just follow this #tweetorial thread 👇
https://t.co/bKnMtKeTs3

[Annals of Oncology @Annals_Oncology]

They analyzed data from 4 multicentre observational studies including 729 patients with a prevalence of 13.2% (96 patients) for BRCA mutations

https://t.co/O5Ztc6ALsy

@Dav_Lorente
@dalameda
@CCattrini
2/2

[Carlo Cattrini 🇮🇹 @CCattrini]

Just out in @Annals_Oncology the CAPTURE study. Big prospective collection #mCRPC patients to study #BRCA. Thanks to @Dolmos77 & @Ecastromarcos for including @UniAvogadro and AOU Novara in this fantastic study. https://t.co/uJF2kuM2fT

[Tom Powles @tompowles1]

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023

[Carlo Cattrini 🇮🇹 @CCattrini]

We are going to collect clinical data and surgery samples of patients with testicular cancer and #Down Syndrome for the #TETRIS study #IGG-06. If you are interested, complete this survey 👉
https://t.co/ghCZND6ZIC
If you are a patient write to: [email protected]

[Carlo Cattrini 🇮🇹 @CCattrini]

Very proud to see my PhD project at @UniGenova published in @SciReports. Thanks to @ALEDIGNUS12 for support at @UniAvogadro. Time to investigate the role of #ceramides in #mCRPC.
Link 👉 https://t.co/ELvFDuwxVV

[pas_rescigno @PasRescigno]

Combination of Parpi and ARSI is a hot and controversial topic. Here our meta-analysis on 3 phaseIII trial https://t.co/5oiTHNSsnT @gbanna74 @carlomessina15 @CCattrini @RebuzziSara @biostat84 @GFornarini @AkashManiam @MatteoBauckneht @AlastairGreyst2 @plummer_ruth @OingC1

[Francesco Massari @fmassari79]

Another important research about the Real-World treatment for metastatic renal cell carcinoma by international ARON Group
Thanks to my friend Matteo Santoni for this our collaboration
@TargetedOnc

[David Olmos @Dolmos77]

We are seeking a motivated bioinformatics / Computational Scientist to work in NGS analysis in a multidisciplinary enviroment at Hosp. Univ. 12 de Octubre Research Institute: https://t.co/Zlk7idfYi7 , see recent examples of our work https://t.co/IVq8JeAMRE If interested send DM

[Francesca Poggio @Poggio_Fra]

Don’t miss poster of the @ASCO merit award recipient @DSoldatoMD on the prognostic role of #BMI within 5 GIM and MIG RCTs! @matteolambe @delmastro_lucia @BlondeauxEva

[Carlo Cattrini 🇮🇹 @CCattrini]

Great honor to have contributed to these impressive results of #CAPTURE study. Save the date of #ASCO23 oral presentation! Many tks to @Dolmos77 and @Ecastromarcos

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Abs#5003 @ASCO #ASCO23: Presence of somatic/germline homologous recombination repair mutations and outcomes in mCRPC #prostatecancer pts receiving first‑line Rx stratified by BRCA status. ➡️ @Dolmos77 @Dav_Lorente @Ecastromarcos @BerUrologia et al. 👉BRCA pts had significantly ⬇️rPFS, PFS2, and OS than total non-BRCA population and significantly ⬇️ PFS2 and OS than non-BRCA HRR+ pts. 👉https://t.co/A5xRggymE2 @OncoAlert @urotoday @PCFnews @Uromigos

[Carlo Cattrini 🇮🇹 @CCattrini]

A special thank to @Dolmos77 for his participation to #YoungOncoGU23 in Verbania. Great presentation from a great leader!

[David Olmos @Dolmos77]

ARPI+PARPi benefit:
BRCAmut mCRPC>>HRRmut mCRPC >> All commers >> HRR Non-mutant mCRPC NBeije @Silke_Gillessen @AdamSharpMedOnc @EAntonarakis @morr316 @ChrisSweens1 @fizazi_karim @Ecastromarcos @quimmateo @sartor_oliver wabida rdewitt mhussain & jdebono
https://t.co/QslgbvVn0b

[Carlo Cattrini 🇮🇹 @CCattrini]

PhD in Translational Oncology 🎉 @UniGenova

[Roberto Iacovelli @DrIacovelli]

📢The first patient has been enrolled in the PErioperative PEmbrolizumab - PE-PE trial (NCT05578664), for patients with olimets #mRCC eligible for surgery and/or RT. A new challenge with more than 30 centres involved in Italy 🇮🇹!

[David Olmos @Dolmos77]

2 RCT have shown benefit from the addition of PARPi to ARPi in 1L mCRPC, rPFS benefit in BRCA>HRRm>all commers>HRR-. How this is going to translate in OS benefit? If as expected all commers benefit is driven by BRCA, Could we justify a more toxicity without clear OS in HRR- #GU23

[Carlo Cattrini 🇮🇹 @CCattrini]

Exciting participation to #prostateoftheart2023. Incredible international speakers and new insights to update our practice in #prostate cancer.
- stop ADT alone for mHSPC
- docetaxel can fit all mHSPC pts except for low-volume metachronous disease
- intensify treatment ASAP

[JNM @JournalofNucMed]

#PSMA PET/CT may be predictive of treatment response in patients with mCRPC, regardless of ongoing systemic therapy. Response assessed by #PETCT is a potentially more significant prognostic factor than PSA for PFS. https://t.co/xZM6dFXDep

#NuclearMedicine @stefanofanti4

[Nick James @Prof_Nick_James]

Delighted that NHS Scotland has now approved abiraterone for high risk M0 prostate cancer. @NHSEngland @NICEComms its urgently time to re-assess this. Big OS and MFS gains with 2y therapy
https://t.co/mUIizwpYgw

[David James Pinato 🇺🇦 @DJPinato]

L’Oncologia @UniAvogadro assume!
In cerca di giovani oncologi con aspirazioni clinico-accademiche per unirsi al team! @ALEDIGNUS12

https://t.co/kQba6o2qcH